Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors
批准号:
10094062
负责人:
George V Aslanidi
金额:
$29.36万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2022-12-31
关键词:
AddressBiologyBiomedical EngineeringCD8-Positive T-LymphocytesCapsidCapsid ProteinsCystic FibrosisDNA cassetteDegradation PathwayDependovirusDevelopmentDiseaseDoseEngineeringEvaluationFrequenciesGenesGenomeGlucocorticoid ReceptorHemophilia BHepatocyteHumanImmune responseImmunologyInflammationInflammatory ResponseInsertional MutagenesisKnowledgeLeadLeber&aposs amaurosisLife Cycle StagesLiverMediatingMolecularMolecular BiologyMusMuscular DystrophiesNF-kappa BNatureParkinson DiseaseParvovirusPathway interactionsPhase I/II Clinical TrialPhosphorylationPrimary carcinoma of the liver cellsPublic HealthRecombinant adeno-associated virus (rAAV)RecombinantsResearch PersonnelRiskSafetySerineSerotypingSingle-Stranded DNASite-Directed MutagenesisSpielmeyer-Vogt DiseaseStructureSurfaceTestingTherapeuticThreonineTyrosineUbiquitinationVirusVirus Integrationadeno-associated viral vectoralpha 1-Antitrypsin Deficiencyaromatic L-amino acid decarboxylase deficiencybaseclinical applicationdesigngene therapygene therapy clinical trialhuman diseaseimprovedinsightmulticatalytic endopeptidase complexnext generationnovelresponsesuccesstraffickingtransduction efficiencyvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The main aims of this multi-PI proposal are to characterize the underlying mechanisms the adeno- associated
virus (AAV)-hepatocyte interactions in general, and to develop number of optimized recombinant (rAAV)
vectors for high-efficiency transduction of hepatocytes with minimal effective dose and with minimal immune
response to capsid.
In recent years, we have undertaken systematic studies to gain a better understanding of the fundamental
molecular mechanisms of AAV-hepatocyte interactions and have made the following significant observations,
which form the basis of the current proposal:
• Identified and site-directed mutagenesis of critical surface-exposed tyrosine, serine, threonine residues on
AAV capsids, and the development of next generation of highly efficient AAV vectors.
• Demonstrated that of transient suppression of the NF-kB pathway minimized pro-inflammatory response
induced by AAV-mediated transduction.
• Observed involvement of the glucocorticoid receptor (GR) pathway in the life cycle of AAV2 vectors.
The following three Specific Aims will be pursued:
Specific Aim 1: Studying of cross-talk between GR and NF-kB pathway during transduction of hepatocytes by
optimized AAV8 vectors and possible implementation to immune response reduction.
Specific Aim 2: Evaluation of safety of optimized AAV8 vectors in human hepatocytes by studying frequency
of integration and possible insertional mutagenesis.
Specific Aim 3: Development of capsid- and genome- optimized AAV8 vectors for efficient transduction of
hepatocytes at low dose and with minimal immune response.
The knowledge gained from these studies will be directly applicable in the development of the next generation
of rAAV vectors for their optimal use in liver-directed gene therapy and particularly for hemophilia B.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.omtm.2023.101147
发表时间:
2023-12-14
期刊:
MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT
影响因子:
--
作者:
[Shoti, Jakob, Qing, Keyun, Keeler, Geoffrey D., Duan, Dongsheng, Byrne, Barry J., Srivastava, Arun]
通讯作者:
Srivastava, Arun
DOI:
10.3389/fmicb.2022.1033615
发表时间:
2022
期刊:
FRONTIERS IN MICROBIOLOGY
影响因子:
5.2
作者:
[Shoti, Jakob, Qing, Keyun, Srivastava, Arun]
通讯作者:
Srivastava, Arun
DOI:
10.1089/hum.2020.074
发表时间:
2020-10
期刊:
Human gene therapy
影响因子:
4.2
作者:
[Krotova K, Aslanidi G]
通讯作者:
Aslanidi G
Optimized Production and Validation of Rationally Designed AAV Vectors for Cockayne Syndrome Gene Therapy
-
批准号:10413533
-
项目类别:
-
资助金额:$60.0万
-
财政年份:2021
-
负责人:George V Aslanidi
-
依托单位:
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors
-
批准号:9886079
-
项目类别:
-
资助金额:$29.36万
-
财政年份:2017
-
负责人:George V Aslanidi
-
依托单位:
Mechanism of high-efficiency transduction of hepatocytes by optimized AAV vectors
-
批准号:9239042
-
项目类别:
-
资助金额:$29.36万
-
财政年份:2017
-
负责人:George V Aslanidi
-
依托单位:
国内基金
海外基金
Journal of Integrative Plant Biology
-
批准号:31024801
-
项目类别:专项基金项目
-
资助金额:24.0万元
-
批准年份:2010
-
负责人:贺萍
-
依托单位: